SANTA CRUZ BIOTECHNOLOGY, INC.

CB2 (M-15): sc-10076



BACKGROUND

The cannabinoid receptors (CB1 and CB2) are G protein-coupled receptors that inhibit adenylate cyclase activity in response to psychoactive cannabinoids. CB1 is expressed in brain tissue and, in low levels, in testes. CB2 is expressed only by cells of the immune system. The cannabinoid receptors mediate most of the cannabinoid-induced responses in a dose-dependent, stereoselective manner. This response system is thought to be involved in specific brain functions, such as nociception, control of movement, memory, and neuro-endocrine regulation, as well as having a possible role in brain development. In addition, CB1 may mediate the addictive behavior involved with the use of psychoactive cannabinoids, such as THC in marijuana.

REFERENCES

- Matsuda, L.A., et al. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
- Gerard, C.M., et al. 1991. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 179: 129-134.
- Munro, S., et al. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
- Shire, D., et al. 1996. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim. Biophys. Acta 1307: 132-136.
- Garcia, D.E., et al. 1998. Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J. Neurosci. 18: 2834-2841.
- Ledent, C., et al. 1999. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404.
- Sugiura, T., et al. 2000. Evidence that 2-arachidonoylglycerol but not Npalmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 275: 605-612.
- 8. Fernandez-Ruiz, J., et al. 2000. The endogenous cannabinoid system and brain development. Trends Neurosci. 23: 14-20.

CHROMOSOMAL LOCATION

Genetic locus: Cnr2 (mouse) mapping to 4 D3.

SOURCE

CB2 (M-15) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of CB2 of mouse origin.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-10076 P, (100 μg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

CB2 (M-15) is recommended for detection of CB2 of mouse and rat origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for CB2 siRNA (m): sc-39913, CB2 shRNA Plasmid (m): sc-39913-SH and CB2 shRNA (m) Lentiviral Particles: sc-39913-V.

Molecular Weight of CB2: 45 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluo-rescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

SELECT PRODUCT CITATIONS

- Ehrhart, J., et al. 2005. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2: 29.
- Ashton, J.C., et al. 2007. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci. Lett. 412: 114-117.
- Raborn, E.S., et al. 2008. The cannabinoid δ-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. J. Neuroimmune Pharmacol. 3: 117-129.
- Romero-Sandoval, A., et al. 2008. Spinal microglial and perivascular cell cannabinoid receptor type 2 activation reduces behavioral hypersensitivity without tolerance after peripheral nerve injury. Anesthesiology 108: 722-734.

RESEARCH USE

For research use only, not for use in diagnostic procedures.